Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

v3.23.1
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($)
Mar. 31, 2023
Mar. 31, 2022
Current assets:    
Cash $ 9,352,538 $ 21,756
Inventory   20,951
Prepaid expenses and deposits 281,475 5,999
Total current assets 9,634,013 48,706
Intangible Software, net 178,403  
Total assets 9,812,416 48,706
Current liabilities:    
Accounts payable and accrued liabilities 705,605 1,115,473
Accounts payable - related parties 18,296 126,183
Note payable 146,250  
Deferred Revenue 38,250  
Due to shareholder   3,758
Total current liabilities 908,401 1,245,414
Total liabilities 908,401 1,245,414
Commitment and contingencies
Stockholders' equity (deficit):    
Ordinary Shares, $0.0001 par value, 492,000,000 shares Authorised; 15,520,269 and 9,949,731 issued and outstanding as of March 31, 2023 and 2022 1,557 999
Reserves 20,921,005 5,363,188
Accumulated deficit (11,794,460) (6,336,966)
Accumulated other loss (1,688) (1,799)
Total stockholders' equity (deficit) (Virax) 9,126,414 (974,578)
Non-controlling interests (222,399) (222,130)
Total stockholders' equity (deficit) 8,904,015 (1,196,708)
Total liabilities and stockholders' equity (deficit) $ 9,812,416 $ 48,706